It may be possible to predict diagnostic transition to schizophrenia and bipolar disorder from machine learning models.

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

Individuals with generalized anxiety disorder (GAD), a condition characterized by daily excessive worry lasting at least six ...

Genomenon, a leader in genomic intelligence, today announced the launch of an enhanced AI-powered integration for its Mastermind Genomic Intelligence Platform. This new capability further refines ...

According to WHO, cognitive health, in particular, is the ability to think, learn, and remember and is crucial for ...

Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the launch of the aPAP ClearPath Dried Blood Spot (DBS) Test in the U.S., an ...

A machine learning model using existing clinical data may help clinicians screen for comorbid anxiety and depression in ...

Individuals with generalized anxiety disorder (GAD), a condition characterized by daily excessive worry lasting at least six ...

DelveInsight's Biosensors Market Insights report provides the current and forecast market analysis, individual leading ...

Multivariate analysis identified elevated D-dimer levels (>750 ng/ml) and reduced serum albumin as independent risk factors ...

The dismal accuracy of some gonorrhoea and chlamydia tests currently on the market is 'worse performance than flipping a coin ...

CRISPR technology offers innovative solutions for pandemic preparedness, enhancing diagnostics, antiviral therapies, and ...